ICON (ICLR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.66
- Estimate
- $2.63
- Surprise
- +1.3%
- Revenue (period 2026-09-30)
- $2.02B
- Score today
- 4.4/10
Revenue source: xbrl.
How the report landed
ICON (ICLR) beat the $2.63 estimate with adjusted EPS of $2.66 — a modest 1.3% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ICLR Sell at 4.4/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +1.3% surprise compares with a -3.2% four-quarter average.
What argues against it
- Target reached (-7.4% upside)
- Quality below floor (3.4 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $182.98
- Stop
- $170.17
The stock trades at 192.6× trailing but 15.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 75 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-28 — shown for context, not personalized investment advice.
ICLR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $14.12B
- P/E (fwd)
- 15.5
- P/E (ttm)
- 192.6
- 52-week range
- $66.57–$203.91
- Off 52-week high
- 10.3%
- RSI (14)
- 75
- Volume vs avg
- 1.03×
- Score today
- 4.4/10